gsk, page-13

I would speculate about a deal after completion of phase 2 trials which I would place between 12 to 18 months, at the earliest as we are talking about pharmaceutical division here.

The preparations for phase 2 trials alone would take several months, I would expect.

We could look at a deal here in 2015/16, which would still be early and well before conclusion of the studies.



On the other hand, why the consumer health developments take so long is making me uncomfortable. It goes all the way back to the onset of the FIM technology program and the listing of the new patents in 2011.
Why did it take 4 years for OBJ and GSK from 2007 to 2011 to move into the dental health sector?

I believe that GSK partnership accelerated only when FIM was initiated. The original FMCG, which disappeared into oblivion, seemed for a long time to be our main target for commercialisation.
GSK progress was very slow for the first years in partnership but has considerably diversified in recent years.



Today's announcement reminded me why I invested in OBJ in the first place in 2007.
The analgesic market was my main motivator.
2007 Jeff was all about the analgesic applications of our technologies and convinced me to massively invest.

P&G and Coty came later into the game through the initialisation of the FIM technologies.



What seems clear up to date is that none of our partners are willing to move in early with a milestone deal to lock in our disruptive technology.
How long stays a technology truly disruptive when it takes 7 years for GSK to move into a phase 2 trials for a pharmaceutical product?

Ex-vivo is the give away in the announcement, we have not reached in vivo or people studies as yet, which indicates we are years away from conclusive results.


We had passed those stages with GSK in 2011 when we were updated on successful in vivo studies with GSK.

Now we are still in ex-vivo studies and possibly move into in-vivo studies in the coming year in the slowest of all sectors our technologies might applied to, the pharmaceutical sector.